Baxter International Inc.’s Stock Price Plummets to $19.16, Marking a Steep 14.54% Drop

Baxter International Inc. (BAX)

19.16 USD -3.26 (-14.54%) Volume: 24.01M

With a notable drop of -14.54% in today’s trading session, Baxter International Inc.’s stock price stands at 19.16 USD, reflecting a year-to-date decrease of -34.29%. The company has seen a substantial trading volume of 24.01M, indicating high market activity around BAX.

Latest developments on Baxter International Inc.

Baxter International Inc. has been experiencing a tumultuous period, with the company reporting sales below analyst estimates in their Q3 earnings, resulting in a 13.5% drop in stock price. The medical products maker faced challenges such as pump issues and low IV demand, leading to a $46M loss. Despite beating Q3 earnings estimates, Baxter had to trim its annual outlook multiple times, causing the stock to hit a 52-week low. The company also faced legal scrutiny and class action lawsuits, further impacting its valuation. With ongoing operational challenges and a reduction in dividend expected for 2026, Baxter International continues to face pressure from investors and shareholders.

Baxter International Inc. on Smartkarma

Analyst coverage of Baxter International on Smartkarma has been positive, with reports from Baptista Research highlighting the company’s financial performance and challenges. In a report titled “Baxter International’s Novum Infusion Pump – Will the Relaunch Ignite a Revenue Surge?”, the analyst discusses the company’s second quarter 2025 earnings results, which showed solid financial performance but also challenges in specific sectors. Sales from continuing operations grew by 4%, but declines in certain segments offset this growth. Despite these challenges, the analyst remains bullish on Baxter International‘s potential.

Another report by Baptista Research, titled “Baxter International Is Building A Tariff Defense Mechanism With Exemption & Sourcing Tactics But Will It Work?”, focuses on the company’s Q1 2025 earnings results. The report highlights robust performance with notable growth across operating segments, exceeding initial projections. Sales from continuing operations increased by 5%, driven by contributions from all segments. Despite challenges reflective of the global economic climate, the analyst maintains a bullish stance on Baxter International‘s outlook.

A look at Baxter International Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Baxter International shows a promising long-term outlook. With high scores in Dividend and Value, the company seems to be a stable investment option. However, lower scores in Growth and Momentum indicate that there may be challenges in the company’s future growth and market performance. Overall, Baxter International‘s Resilience score suggests that the company is equipped to withstand economic fluctuations and industry challenges.

Baxter International Inc. is known for developing, manufacturing, and marketing products related to various medical conditions such as hemophilia, immune disorders, and kidney disease. Their products are widely used in hospitals, dialysis centers, nursing homes, and research laboratories. With a strong focus on dividends and value, Baxter International may be a reliable choice for investors looking for stability in the healthcare sector.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma